Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: DMB who wrote (1514)	3/11/1998 2:45:00 AM
From: Maurice Winn	Read Replies (1) \| Respond to of 1762

DMB, thanks. Regarding the mechanism by which lymphoma cells die from Rituxan, yes, that was what Dr Saven suggested too. Maybe simple mechanical damage due to molecular banging around eh? Well, I was a civil engineer originally and physical effects seem so much simpler than all this electron flow, bonding and chemistry. I get the impression that the Malaghan Institute is doing something a little different. I guess results will be the thing to watch, not the claims. Regards, Maurice

To: DMB who wrote (1514)	4/1/1998 4:46:00 PM
From: Maurice Winn	Read Replies (1) \| Respond to of 1762

So, what's going on? 50,000 people per year getting NHL in USA. Half of them live for 5 years or so. Low grade patients live much longer than the intermediate and high grade patients who fail chemotherapy and radiation. Follicular and CD20 expressing patients can benefit from Rituxan. The product has been on sale for 4 months. So, how come there seems to be little interest here? There must be quarter of a million people carting lymphoma around with them right now in the USA - give or take a few. I wonder if they invest in cures. I wonder if they read about Rituxan. Techniclone is coming up to Phase III trials for Oncolym. It could well compete directly with Rituxan, not or cold, in the follicular and low grade patient group. Bexxar is getting ready too. Does anybody know what patients are experiencing with Rituxan? There must be 10s of thousands of them by now who have been treated. If not why not? Are oncologists so reticent about using a new product that they negligently omit to offer it to their patients because it is unproven although risks are low. I realize that Silicon Investor has a fairly limited clientele, but nevertheless, the dearth of interest is palpable. Any ideas on what is happening with Rituxan in people with follicular and other lymphomas? Anybody? Maurice